idarubicin has been researched along with Disease Exacerbation in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (18.52) | 18.2507 |
| 2000's | 12 (44.44) | 29.6817 |
| 2010's | 9 (33.33) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Arao, Y; Fujimoto, K; Fukaya, K; Furusawa, K; Haga, T; Hiraiwa, H; Kano, N; Kato, H; Kondo, T; Kuwayama, T; Morimoto, R; Murohara, T; Mutsuga, M; Oishi, H; Okumura, T; Sawamura, A; Shimizu, S; Sugiura, Y; Usui, A; Watanabe, N; Yamaguchi, S; Yokoi, T | 1 |
| Balakrishnan, VS | 1 |
| Bosi, A; Coltro, G; Guglielmelli, P; Mannelli, F; Pacilli, A; Vannucchi, AM | 1 |
| Fernández-Sojo, J; Oliveras Vilà, T; Ribera, JM; Vives, S | 1 |
| Tohyama, K | 1 |
| Bardou, M; Bedenne, L; Bonnetain, F; Boulin, M; Cercueil, JP; Chauffert, B; Dabakuyo, S; Denys, A; Grandvuillemin, A; Guerard, P; Guiu, B; Hillon, P; Jouve, JL; Lepage, C; Minello, A; Wendremaire, M | 1 |
| Chen-Liang, TH; Florensa, L; Jerez, A; Ortuño, FJ | 1 |
| Dou, MH; Hu, C; Huang, J; Jin, J; Li, Y; Lou, YJ; Luo, YW; Ma, LY; Mao, LP; Mei, C; Niu, LM; Ren, YL; Tong, HY; Wang, JH; Wei, JY; Xie, LL; Xu, GX; Ye, L; Ye, XN; Yu, WJ; Zhou, XP | 1 |
| Ardeshna, K; Badat, M; Cheesman, S; D'Sa, S; Joshi, R; Lambert, J; Linch, D; Maciocia, P; Mohamedbhai, S; Pule, M | 1 |
| Ando, K; Kawada, H; Murayama, H; Nakamura, N; Ogawa, Y; Ohmachi, K; Suzuki, R; Tsuboi, K | 1 |
| Fenaux, P; Ghédira, H; Gouider, E; Jeddi, R; Meddeb, B; Mnif, S | 1 |
| Bengala, C; Biadi, O; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Favre, C; Fogli, S; Guarneri, V; Innocenti, F; Mariani, M; Pazzagli, I | 1 |
| Higa, T; Imai, A; Imamura, M; Kasai, M; Kiyama, Y; Kobayashi, N; Kondo, Y; Miyokawa, N; Ogasawara, M; Ogawa, T; Sato, K; Tanaka, J; Toubai, T | 1 |
| Glasmacher, A; Gorschlüter, M; Mey, U; Schmidt-Wolf, IG; Schwerdtfeger, R | 1 |
| Antoneli, CB; Arias, VE; Chojniak, MM; Novaes, PE; Ribeiro, Kde C; Sakamoto, LH | 1 |
| Cho, SG; Eom, KS; Kim, CC; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Min, CK; Min, WS | 1 |
| Angus, B; Galloway, MJ; Jackson, GH; Lessells, AM; Lucraft, HH; Prescott, RJ; Proctor, SJ; Summerfield, GP; Taylor, PR; White, JM | 1 |
| Albitar, M; Day, A; Do, KA; Estey, E; Giles, FJ; Jilani, I; Johnson, M; Kantarjian, H; Keating, M; O'brien, S; Pierce, S; Verstovsek, S | 1 |
| Baldicchi, L; Corneo, GM; Mangiagalli, M; Miccolis, IR; Pioltelli, P; Pogliani, EM | 1 |
| Chalmers, EA; Clark, RE; Crotty, G; Franklin, IM; Goldstone, AH; Hepplestone, A; Kelsey, SM; McBride, N; McCann, SR; Newland, AC; Sharp, RA; Singer, IO; Sproul, AM; Tansey, PJ; Watson, W | 1 |
| Biondi, A; Coppi, MR; Liso, V; Mestice, A; Mininni, D; Palumbo, G; Pogliani, EM; Rossi, V; Specchia, G; Teruzzi, E | 1 |
| Mollee, PN; Rodwell, R; Taylor, D; Taylor, KM; Williams, B | 1 |
| Kulkarni, S; Mainwaring, PN; Powles, RL; Raje, N; Ramiah, V; Sumpter, K; Treleaven, J | 1 |
| Battista, R; Bendandi, M; Cellini, C; Ciccone, F; De Renzo, A; Gentilini, P; Gherlinzoni, F; Gobbi, M; Guardigni, L; Lauta, VM; Magagnoli, M; Marra, R; Mazza, P; Moretti, L; Ricciuti, F; Ronconi, F; Stefoni, V; Tura, S; Zaccaria, A; Zinzani, PL | 1 |
| Anderson, A; Cameron, DA; Howell, A; Leonard, RC; Ostrowski, J | 1 |
| Ahmed, T; Feldman, EJ; Kancherla, R; Liu, D; Papageorgio, C; Pozzuoli, M; Seiter, K; Sreekantaiah, C; Weisberger, J; Weiss, M | 1 |
| Nilsson, B; Rödjer, S; Westin, J | 1 |
3 review(s) available for idarubicin and Disease Exacerbation
| Article | Year |
|---|---|
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles | 2014 |
Trilateral retinoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Disease Progression; Etoposide; Eye Enucleation; Eye Neoplasms; Fatal Outcome; Female; Humans; Idarubicin; Ifosfamide; Male; Methotrexate; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Neoplastic Syndromes, Hereditary; Pinealoma; Prognosis; Retinoblastoma; Vincristine | 2007 |
Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 11; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytarabine; Disease Progression; Disease-Free Survival; Enzyme Inhibitors; Etoposide; Female; Humans; Idarubicin; Incidence; Karyotyping; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm Proteins; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Topoisomerase II Inhibitors; Treatment Outcome; Tretinoin | 2001 |
9 trial(s) available for idarubicin and Disease Exacerbation
| Article | Year |
|---|---|
Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Quality of Life; Survival Rate; Treatment Outcome | 2014 |
High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Child; Child, Preschool; Disease Progression; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Prognosis; Survival Analysis; Syndrome; Tretinoin; Young Adult | 2010 |
The significance of minimal residual disease kinetics in adults with newly diagnosed PML-RARalpha-positive acute promyelocytic leukemia: results of a prospective trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Female; Humans; Idarubicin; Kinetics; Leukemia, Promyelocytic, Acute; Life Tables; Male; Mercaptopurine; Methotrexate; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Prognosis; Proportional Hazards Models; Prospective Studies; Remission Induction; Survival Analysis; Tretinoin | 2006 |
The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotland and Newcastle Lymphom
Topics: Administration, Oral; Adolescent; Adult; Aged; Chlorambucil; Dexamethasone; Disease Progression; Drug Therapy, Combination; England; Female; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Survival Rate; Time Factors; Treatment Failure | 2006 |
Autologous transplantation in chronic myeloid leukaemia using peripheral blood stem cells.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Disease Progression; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 1998 |
Oral idarubicin as a single agent therapy in patients with relapsed or resistant multiple myeloma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Humans; Idarubicin; Methylprednisolone; Middle Aged; Multiple Myeloma; Remission Induction; Salvage Therapy; Thrombocytopenia; Treatment Failure; Vincristine | 1999 |
Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Disease Progression; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Lymphocytic, Chronic, B-Cell; Linear Models; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Vidarabine | 2000 |
Idarubicin and cyclophosphamide--an active oral chemotherapy regimen for advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Agranulocytosis; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Fatigue; Female; Humans; Idarubicin; Infections; Middle Aged; Thrombocytopenia | 2000 |
Do anthracyclines have a role in the therapy of multiple myeloma?
Topics: Aged; Aged, 80 and over; Agranulocytosis; Antibiotics, Antineoplastic; Disease Progression; Female; Humans; Idarubicin; Male; Middle Aged; Multiple Myeloma; Recurrence; Remission Induction; Salvage Therapy; Thrombocytopenia; Treatment Failure | 2000 |
15 other study(ies) available for idarubicin and Disease Exacerbation
| Article | Year |
|---|---|
Pathological changes of the myocardium in reworsening of anthracycline-induced cardiomyopathy after explant of a left ventricular assist device.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cardiotoxicity; Daunorubicin; Device Removal; Disease Progression; Female; Fibrosis; Heart-Assist Devices; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Myocardium; Time Factors; Ventricular Function, Left | 2020 |
Escalated anthracycline dose in adult AML.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Cytarabine; Disease Progression; Disease-Free Survival; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2017 |
A life-threatening ruxolitinib discontinuation syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Diagnosis, Differential; Disease Progression; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Janus Kinase 2; Leukemia, Myeloid, Acute; Middle Aged; Nitriles; Pneumonia; Protein Kinase Inhibitors; Pulmonary Embolism; Pyrazoles; Pyrimidines; Remission Induction; Respiratory Distress Syndrome; Substance Withdrawal Syndrome; Thrombocythemia, Essential; Tomography, X-Ray Computed | 2017 |
[Exudative pericardial effusion and oligoarthritis in a patient newly diagnosed with myelodysplastic syndrome].
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Arthritis; Azacitidine; Cytarabine; Disease Progression; Etoposide; Fatal Outcome; Hepatomegaly; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Pericardial Effusion; Pleural Effusion; Serositis | 2014 |
[Neoplastic mastocytosis evolving from a poor prognosis acute myeloid leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Fatal Outcome; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunophenotyping; Leukemia, Mast-Cell; Leukemia, Myeloid, Acute; Mast Cells; Mutation; Neoplasm Proteins; Neoplastic Stem Cells; Prognosis; Vidarabine | 2015 |
Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Cytarabine; Decitabine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Recurrence; Remission Induction; Treatment Outcome | 2016 |
Treatment of diffuse large B-cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS-penetrating R-IDARAM chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Idarubicin; Infusions, Intravenous; Injections, Spinal; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Retrospective Studies; Rituximab; Treatment Outcome | 2016 |
[Granulocytic sarcoma of the prostate presenting with urinary obstruction which progressed to acute myeloid leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Dysuria; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplasms, Second Primary; Prostatic Neoplasms; Remission Induction; Sarcoma, Myeloid | 2008 |
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Daunorubicin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Idarubicin; Melphalan; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Taxoids; Thiotepa; Time Factors; Transplantation Conditioning; Treatment Outcome | 2003 |
A case of leukemia of the appendix presenting as acute appendicitis.
Topics: Aged; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Appendectomy; Appendicitis; Appendix; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease Progression; Fatal Outcome; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Mercaptopurine; Sarcoma, Myeloid | 2003 |
Acute myeloid leukemia with near-triploid karyotype and extramedullary involvement of mediastinum.
Topics: Adult; Antineoplastic Agents; Bone Marrow Cells; Central Nervous System; Cytarabine; Disease Progression; Etoposide; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Mediastinum; Polyploidy; Prognosis; Stem Cell Transplantation; Tomography, X-Ray Computed | 2005 |
Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Cytarabine; Disease Progression; Female; HLA Antigens; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Predictive Value of Tests; Proportional Hazards Models; Remission Induction; Solubility; Topotecan; Treatment Outcome; Vidarabine | 2007 |
Idarubicin in combination with cytarabine and VP-16 in the treatment of post myelodysplastic syndrome acute myeloblastic leukemia (MDS-AML).
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction | 1995 |
Extramedullary involvement in patients with acute promyelocytic leukemia: a report of seven cases.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Brain Neoplasms; Cytarabine; Daunorubicin; Disease Progression; Fatal Outcome; Female; Gene Amplification; Gene Rearrangement; Humans; Idarubicin; Immunophenotyping; Leukemia, Promyelocytic, Acute; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Skin Neoplasms; Translocation, Genetic; Tretinoin | 1998 |
Long-term molecular remission in promyelocytic transformation of myeloproliferative disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cytarabine; Daunorubicin; Disease Progression; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Polycythemia Vera; Preleukemia; Prognosis; Remission Induction; Thrombocythemia, Essential; Thrombophilia; Translocation, Genetic; Tretinoin | 1999 |